Johanna Schleutker
PhD, Professor of Medical Genetics
Cancer, Infections and Immunity johanna.schleutker@utu.fi +358 29 450 2726 +358 50 443 7237 Kiinamyllynkatu 10 Turku ORCID-tunniste: https://orcid.org/0000-0002-1863-0305 |
Cancer genetics; hereditary cancer; genomics; human genetics
Johanna Schleutker got her PhD in 1995 in University of Turku, Faculty of Medicine.The topic of her doctoral thesis was "Linkage disequilibrium is Salla disease; positioning of the sialic acid transport defect". She then moved to University of Tampere, and did her post doc in 1996-1998 in the Cancer Genetics research group of Professor Olli Kallioniemi. Her career continued in the US where she spent the years of 1999-2000 working as a research associate at the National Human Genome Research Institute, National Institutes of Health, Bethesda, MD. During the NIH years, she studied genetics of familial prostate cancer in the group of Dr. Jeffrey M.Trent. After her return to Finland, Schleutker started her own research group in 2001 at the Insitute of Medical Technology, University of Tampere, and has ever since focused her studies on genetics and genetic susceptibility of prostate and breast cancer. Schleutker got a professorship in University of Tampere in 2008. In 2011 she started as a professor of medical genetics in University of Turku.
The Schleutker group "Genetic Predisposition to Cancer" is studying both breast and prostate cancer genetics, the main emphasis being on prostate cancer. Of all cancers, prostate cancer (PrCa) has been reported as one of the most heritable diseases: genetic factors have been estimated to account for 57% of the risk. The goal is to identify and characterize predisposing genes and variants, especially those affecting aggressive outcome, including treatment responses to therapies. Further, the aim is to develop tools for prognostic purposes, i.e. prognostic biomarkers. The group has identified many significant genomic risk regions, candidate genes and variants, which have been then further profiled and characterized by functional studies. The group has produced (by 2021) 12 PhD degrees and published over 190 original, peer-reviewed articles in international journals.
Genetics, cancer genetics, hereditary cancer, genomics, molecular biology.
- Hereditary prostate cancer in Finland: fine-mapping validates 3p26 as a major predisposition locus (2005)
- Human Genetics
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Combined genome-wide scan for prostate cancer susceptibility genes (2004)
- JNCI: Journal of the National Cancer Institute
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Germline mutation analysis of the androgen receptor gene in Finnish patients with prostate cancer (2004)
- Journal of Urology
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Kruppel-like factor 6 germ-line mutations are infrequent in finnish hereditary prostate cancer (2004)
- Journal of Urology
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer (2004)
- Nature Genetics
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - BRCA1 and BRCA2 mutations have no major role in predisposition to prostate cancer in Finland (2003)
- Journal of Medical Genetics
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - CHEK2 variants associate with hereditary prostate cancer (2003)
- British Journal of Cancer
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Genome-wide scan for linkage in Finnish hereditary prostate cancer (HPC) families identifies novel susceptibility loci at 11q14 and 3p25-26 (2003)
- Prostate
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Germ-line alterations in MSR1 gene and prostate cancer risk (2003)
- Clinical Cancer Research
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - New paraoxonase 1 polymorphism I102V and the risk of prostate cancer in Finnish men (2003)
- JNCI: Journal of the National Cancer Institute
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - No fumarate hydratase (FH) mutations in hereditary prostate cancer (2003)
- Journal of Medical Genetics
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Androgen receptor CAG polymorphism and prostate cancer risk (2002)
- Human Genetics
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer (2002)
- American Journal of Human Genetics
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Germline mutations in the ribonuclease L gene in families showing linkage with HPC1 (2002)
- Nature Genetics
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Physical and transcript map of the hereditary prostate cancer region at Xq27 (2002)
- Genomics
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - A missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A2) is not associated with prostate cancer in Finland (2001)
- British Journal of Cancer
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Association of E-cadherin germ-line alterations with prostate cancer (2001)
- Clinical Cancer Research
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer (2001)
- Cancer Research
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Genetic changes in familial prostate cancer by comparative genomic hybridization (2001)
- Prostate
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Relatives of prostate cancer patients have an increased risk of prostate and stomach cancers: a population-based, cancer registry study in Finland (2001)
- Cancer Causes and Control
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )